Literature DB >> 16741296

18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.

Steven M Larson1, Lawrence H Schwartz.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16741296

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  30 in total

1.  The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Authors:  I Zerizer; A Al-Nahhas; D Towey; P Tait; B Ariff; H Wasan; G Hatice; N Habib; T Barwick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-30       Impact factor: 9.236

2.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

3.  Reply to Rahbar K et al.

Authors:  Madhav Prasad Yadav; Sanjana Ballal; Madhavi Tripathi; Chandrasekhal Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-01       Impact factor: 9.236

4.  Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer.

Authors:  Kim Francis Andersen; Kristin Skougaard; Anne Lerberg Nielsen; Helle Westergren Hendel
Journal:  Oncol Lett       Date:  2012-04-18       Impact factor: 2.967

5.  99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation.

Authors:  Sabrina Pesnel; Yves Guminski; Arnaud Pillon; Stéphanie Lerondel; Thierry Imbert; Nicolas Guilbaud; Anna Kruczynski; Christian Bailly; Alain Le Pape
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-10       Impact factor: 9.236

6.  Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management.

Authors:  Long Sun; Yong-Song Guan; Wei-Ming Pan; Gui-Bing Chen; Zuo-Ming Luo; Hua Wu
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

7.  2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.

Authors:  Juliana Maynard; Sally-Ann Ricketts; Christelle Gendrin; Phillippa Dudley; Barry R Davies
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening.

Authors:  Peter Man-Un Ung; Wenxin Song; Lili Cheng; Xinbin Zhao; Hailin Hu; Ligong Chen; Avner Schlessinger
Journal:  ACS Chem Biol       Date:  2016-05-11       Impact factor: 5.100

10.  SLC Transporters: Structure, Function, and Drug Discovery.

Authors:  Claire Colas; Peter Man-Un Ung; Avner Schlessinger
Journal:  Medchemcomm       Date:  2016-03-28       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.